Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics, SelectHealth Sign Coverage Agreement for Thyroid Cancer Tests

NEW YORK— Interpace Diagnostics announced today that it has signed an agreement with SelectHealth/Intermountain Healthcare to offer its thyroid cancer detection assays to SelectHealth's 850,000 members in Utah and Idaho. 

As part of the agreement, physicians across SelectHealth's entire network can now use Interpace's ThyGeNext and ThyraMir assays to test questionable thyroid nodules for potential evidence of thyroid cancer.

In addition, Interpace said it will act as an in-network laboratory for these services to SelectHealth's members. 

"This continues the trend we have seen among other healthcare plans, both national and regional, to make our unique ThyGeNext/ThyraMir combination tests available to their members," Interpace CEO Jack Stover said in a statement.